Literature DB >> 24073941

Antimicrobial therapies for Q fever.

Gilbert J Kersh1.   

Abstract

Q fever is caused by the bacterium Coxiella burnetii and has both acute and chronic forms. The acute disease is a febrile illness often with headache and myalgia that can be self-limiting, whereas the chronic disease typically presents as endocarditis and can be life threatening. The normal therapy for the acute disease is a 2 week course of doxycycline, whereas chronic disease requires 18-24 months of doxycycline in combination with hydroxychloroquine. Alternative treatments are used for pregnant women, young children and those who cannot tolerate doxycycline. Doxycycline resistance is rare, but has been reported. Co-trimoxazole is a currently recommended alternative treatment, but quinolones, rifampin and newer macrolides may also provide some benefit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24073941      PMCID: PMC4608426          DOI: 10.1586/14787210.2013.840534

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  64 in total

1.  Studies on Q fever in man.

Authors:  A S BENENSON; W D TIGERTT
Journal:  Trans Assoc Am Physicians       Date:  1956

2.  An assessment of health status among medical research volunteers who served in the Project Whitecoat program at Fort Detrick, Maryland.

Authors:  Phillip R Pittman; Sarah L Norris; Kevin M Coonan; Kelly T McKee
Journal:  Mil Med       Date:  2005-03       Impact factor: 1.437

Review 3.  Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii.

Authors:  Daniel E Voth; Robert A Heinzen
Journal:  Cell Microbiol       Date:  2007-04       Impact factor: 3.715

4.  Activity of telithromycin against thirteen new isolates of C. burnetii including three resistant to doxycycline.

Authors:  Jean-Marc Rolain; Frédéric Lambert; Didier Raoult
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

5.  Therapeutic impact of the correlation of doxycycline serum concentrations and the decline of phase I antibodies in Q fever endocarditis.

Authors:  Audrey Lecaillet; Marie-Noëlle Mallet; Didier Raoult; Jean-Marc Rolain
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

6.  Seroprevalence of Q fever in the United States, 2003-2004.

Authors:  Alicia D Anderson; Deanna Kruszon-Moran; Amanda D Loftis; Geraldine McQuillan; William L Nicholson; Rachel A Priestley; Amanda J Candee; Nicole E Patterson; Robert F Massung
Journal:  Am J Trop Med Hyg       Date:  2009-10       Impact factor: 2.345

Review 7.  Ocular toxicity of hydroxychloroquine.

Authors:  Rodney Tehrani; Rochella A Ostrowski; Richard Hariman; Walter M Jay
Journal:  Semin Ophthalmol       Date:  2008 May-Jun       Impact factor: 1.975

8.  Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy.

Authors:  Xavier Carcopino; Didier Raoult; Florence Bretelle; Léon Boubli; Andreas Stein
Journal:  Clin Infect Dis       Date:  2007-07-17       Impact factor: 9.079

9.  Coxiella burnetii infection of aortic aneurysms or vascular grafts: report of 30 new cases and evaluation of outcome.

Authors:  E Botelho-Nevers; P-E Fournier; H Richet; F Fenollar; H Lepidi; C Foucault; A Branchereau; P Piquet; M Maurin; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-09       Impact factor: 3.267

10.  Maternofetal consequences of Coxiella burnetii infection in pregnancy: a case series of two outbreaks.

Authors:  Katharina Boden; Andreas Brueckmann; Christiane Wagner-Wiening; Beate Hermann; Klaus Henning; Thomas Junghanss; Thomas Seidel; Michael Baier; Eberhard Straube; Dirk Theegarten
Journal:  BMC Infect Dis       Date:  2012-12-19       Impact factor: 3.090

View more
  32 in total

1.  Seroprevalence and Risk Factors for Coxiella burnetii in Jordan.

Authors:  Mohammad M Obaidat; Lile Malania; Paata Imnadze; Amira A Roess; Alaa E Bani Salman; Ryan J Arner
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

2.  Myocarditis: A rare manifestation of acute Q fever infection.

Authors:  Andrew Jacobson; Piraon Sutthiwan
Journal:  J Cardiol Cases       Date:  2019-06-01

3.  Rapid molecular diagnosis of infective aortic valve endocarditis caused by Coxiella burnetii.

Authors:  Oliver Kumpf; Pascal Dohmen; Martin Ertmer; Fabian Knebel; Alexandra Wiessner; Judith Kikhney; Annette Moter; Sascha Treskatsch
Journal:  Infection       Date:  2016-06-23       Impact factor: 3.553

Review 4.  Coxiella burnetii: international pathogen of mystery.

Authors:  Amanda L Dragan; Daniel E Voth
Journal:  Microbes Infect       Date:  2019-09-28       Impact factor: 2.700

5.  Development and validation of 2 probe-hybridization quantitative PCR assays for rapid detection of a pathogenic Coxiella species in captive psittacines.

Authors:  Alison J Flanders; Brian Speer; Drury R Reavill; John F Roberts; April L Childress; Alvin Atlas; James F X Wellehan
Journal:  J Vet Diagn Invest       Date:  2020-03-19       Impact factor: 1.279

6.  Coxiella burnetii Intratracheal Aerosol Infection Model in Mice, Guinea Pigs, and Nonhuman Primates.

Authors:  A E Gregory; E J van Schaik; K E Russell-Lodrigue; A P Fratzke; J E Samuel
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

Review 7.  Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.

Authors:  Domenico Plantone; Tatiana Koudriavtseva
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 3.580

8.  A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.

Authors:  Thomas E J Chavas; Fang-Yi Su; Selvi Srinivasan; Debashish Roy; Brian Lee; Lara Lovelace-Macon; Guilhem F Rerolle; Elaine Limqueco; Shawn J Skerrett; Daniel M Ratner; T Eoin West; Patrick S Stayton
Journal:  J Control Release       Date:  2020-11-19       Impact factor: 9.776

9.  Pediatric Q Fever.

Authors:  Cara C Cherry; Gilbert J Kersh
Journal:  Curr Infect Dis Rep       Date:  2020-03-18       Impact factor: 3.725

10.  Acute Q Fever in an Ankylosing Spondyloarthritis Patient Treated with Etanercept.

Authors:  A Guiga; D Khalifa; W Ben Yahia; N El Amri; A Atig; N Ghannouchi
Journal:  Case Rep Rheumatol       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.